Biosurfit SA (“biosurfit”), the in vitro point-of-care (PoC) diagnostics company, is pleased to announce that it has reached a significant commercial milestone, and also provides an update on recent progress.

At the end of February 2017, biosurfit achieved a key commercial milestone by delivering the 500th spinit point-of-care instrument to a European customer. With a commercial presence in over 20 countries, a growing distributor network and a current order backlog of approximately 150 instruments, biosurfit is on track to have over 1,000 spinit instruments in daily use by customers by the end of 2017.

Biosufit is building a suite of tests on its proprietary spinit device. With the CE-Marking of the new HbA1c (Haemoglobin A1c) test in November 2016, along with CRP (c-reactive protein) and BC (blood count), spinit offers a comprehensive menu of fast, easy to perform laboratory quality tests in a point-of-care instrument.

Spinit is the first and only point-of-care diagnostic system capable of performing all three of the major blood tests (haematology, immunoassays and clinical chemistry) on the same instrument. This combination of different detection methods on the CD/DVD format of the spinit disposable disc, along with powerful microfluidics, is facilitating the development of a pipeline of tests. A lipids panel, an inflammation panel and a D-dimer test are all currently in the advanced stages of development are expected to launch over the next few months.

João Garcia da Fonseca, chief executive officer of biosurfit, commented: “The delivery of 500 spinit devices marks a significant commercial milestone for biosurfit. We are very encouraged by the growing customer interest in our spinit system and our recent commercial progress. We are targeting over 1,000 instruments in daily use by the end of 2017 and are looking forward to continuing the roll-out and commercialisation of the expanded spinit test menu during the course of the year.”